ELCC 2019 | Multiple-line TKIs to prolong chemo-free period in EGFRm+ NSCLC

Nicolas Girard

Nicolas Girard, MD, PhD, from Claude Bernard University, Lyon, France discusses the management strategies in EGFRm+ non-small cell lung cancer (NSCLC) patients after completing chemotherapy. Speaking at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland, Prof. Girard explains how multiple lines of EGFR TKIs can be used to target the evolving molecular profile of NSCLC at different stages, focusing on the use osimertinib to treat resistance mutations as the tumor progresses.

Share this video